Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Anna Pedret‐Dunn"'
Autor:
Karl Brendel, Tanios Bekaii‐Saab, Patrick M Boland, Farshid Dayyani, Andrew Dean, Teresa Macarulla, Fiona Maxwell, Kabir Mody, Anna Pedret‐Dunn, Zev A Wainberg, Bin Zhang
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1550-1563 (2021)
Abstract Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinotecan and its active metabolite SN‐38. A population pharmacokinetic (PK) model was developed based on data from seven studies (N = 440). Adeq
Externí odkaz:
https://doaj.org/article/e00fe99ece8b44b19ef2e7b6979ee045
Autor:
Xiaoyan Li, Huaifang Li, Hong Shi, Xiaomao Li, Renfeng Zhou, Dan Lu, Yunlang Cai, Yingfang Zhou, Patrick Cabri, Xiaofeng Shi, Anna Pedret-Dunn, Jinhua Leng
Publikováno v:
Advances in therapy. 39(10)
This phase 3, randomized, open-label, active-controlled, multicenter study investigated the efficacy of triptorelin pamoate prolonged-release (PR) 3-month in Chinese patients with endometriosis by demonstrating the noninferiority of the 3-month formu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13f8d1d2f78f0c1cae4beb91d7c40a56
https://pubmed.ncbi.nlm.nih.gov/35947347
https://pubmed.ncbi.nlm.nih.gov/35947347
Autor:
Teresa Macarulla, K. Brendel, Patrick McKay Boland, Kabir Mody, Anna Pedret-Dunn, Tanios Bekaii-Saab, Bin Zhang, Farshid Dayyani, Fiona Maxwell, Zev A. Wainberg, Andrew Dean
Publikováno v:
CPT: pharmacometrics & systems pharmacology, vol 10, iss 12
Scientia
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1550-1563 (2021)
Scientia
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1550-1563 (2021)
Pharmacokinetics; Liposomal irinotecan; Safety Farmacocinética; Irinotecán liposomal; Seguridad Farmacocinètica; Irinotecan liposomal; Seguretat Liposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinoteca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d425997114a3ce62ba0115186904fe7
https://escholarship.org/uc/item/4f56r0n3
https://escholarship.org/uc/item/4f56r0n3
Autor:
Patricia Rich, V. Gutierrez Calderon, Atilio Navarro, R. Bernabe Caro, Theresa M. Hayes, O. Juan-Vidal, Bin Zhang, Paul A. Bunn, M. Jove Casulleras, Afshin Dowlati, Anna Pedret-Dunn, K. Brendel, Y. Moore, J. Kokhreidze, David R. Spigel, Luis Paz-Ares, Santiago Ponce, Y. Chen
Publikováno v:
Annals of Oncology. 31:S1038-S1039
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5636f9e5a90749139debf78291dbe148
https://doi.org/10.1016/j.annonc.2020.08.1554
https://doi.org/10.1016/j.annonc.2020.08.1554
Autor:
Bin Zhang, Teresa Macarulla, K. Brendel, Andrew Dean, Anna Pedret-Dunn, Zev A. Wainberg, Fiona Maxwell, Farshid Dayyani, Christopher A. Lieu, Bruce Belanger, Y. Moore
Publikováno v:
Annals of Oncology. 30:v263
Background Liposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan which prolongs circulation of irinotecan and its active metabolite SN-38. This analysis describes the population pharmacokinetics (PK) of nal-IRI in patients with vari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c41385f0321e598e3e61bae8b08cde95
https://doi.org/10.1093/annonc/mdz247.018
https://doi.org/10.1093/annonc/mdz247.018
Autor:
Carey K. Anders, Fiona Maxwell, Anna Pedret-Dunn, Jasgit C. Sachdev, Cynthia X. Ma, Hyo S. Han, Pamela N. Munster, Donald W. Northfelt
Publikováno v:
Journal of Clinical Oncology. 37:e12003-e12003
e12003 Background: Irinotecan liposome injection (nal-IRI) uses intraliposomal stabilisation technology to enable high drug load and in-vivo stability. This analysis characterizes the PK profile of nal-IRI in pts with mBC. Methods: The expansion of N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b08d5d3891fd6a633fbbe80006f2c41c
https://doi.org/10.1200/jco.2019.37.15_suppl.e12003
https://doi.org/10.1200/jco.2019.37.15_suppl.e12003
Autor:
Sabine Schaertl, Celia Dominguez, Douglas Macdonald, Maria Beconi, Marie Li, Stephen Martin Courtney, Ignacio Munoz-Sanjuan, Sayeh Erfan, Richard W Marston, Frederick Arthur Brookfield, Darshan Gunvant Vaidya, Anna Pedret-Dunn, Michael Prime, Laura Reed, Peter Johnson, John Wityak, Siw F. Johnsen
Publikováno v:
ACS Medicinal Chemistry Letters. 3:1024-1028
We report a series of irreversible transglutaminase 2 inhibitors starting from a known lysine dipeptide bearing an acrylamide warhead. We established new SARs resulting in compounds demonstrating improved potency and better physical and calculated pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::876741143e5614a16215dc697c0077d5
https://doi.org/10.1021/ml300241m
https://doi.org/10.1021/ml300241m
Autor:
Sabine Schaertl, Simon Gaines, Michael Prime, Celia Dominguez, Maria Beconi, John Wityak, Osamu Ichihara, Stephen Martin Courtney, Richard W Marston, Frederick Arthur Brookfield, Darshan Gunvant Vaidya, Leticia Toledo-Sherman, Anna Pedret-Dunn, Douglas Macdonald, Helen Williams, Marie Li, Laura Reed, Ignacio Munoz-Sanjuan
Publikováno v:
ACS Medicinal Chemistry Letters. 3:731-735
A new series of potent TG2 inhibitors are reported that employ a 4-aminopiperidine core bearing an acrylamide warhead. We establish the structure-activity relationship of this new series and report on the transglutaminase selectivity and in vitro ADM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::300f5e3ba55ab9209e594837eeb54029
https://doi.org/10.1021/ml3001352
https://doi.org/10.1021/ml3001352
Autor:
Robert K. Y. Cheng, Celia Dominguez, Osamu Ichihara, Douglas Macdonald, Ignacio Munoz-Sanjuan, Mark A. Brooks, Andreas Ebneth, Leticia Toledo-Sherman, Michael Prime, Ian Toogood-Johnson, Sayeh Erfan, John Wityak, Richard W Marston, Frederick Arthur Brookfield, Darshan Gunvant Vaidya, Stephen Martin Courtney, Peter Johnson, Anna Pedret-Dunn, Andreas Scheel, Dirk Winkler, Christopher John Yarnold, Sabine Schaertl, Ole A. Andersen, Shilpa Palan, Maria Beconi, Brunella Felicetti, Siw F. Johnsen, John J. Barker, Jordan J. Palfrey, Ina Sternberger
Publikováno v:
Journal of Medicinal Chemistry. 55:1021-1046
Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58fc19f1a7931a01abe7cc99692b57ab
https://doi.org/10.1021/jm201310y
https://doi.org/10.1021/jm201310y
Autor:
Stephan Georg Mueller, Anna Pedret-Dunn, Natacha Prevost, Clemens Moeller, Christopher Brown, Juergen Prestle, Bernd Nosse, Stefan Scheuerer, Marcus Schindler, Mark Whittaker, Alexander Heifetz, Heather Tye
Publikováno v:
Bioorganicmedicinal chemistry letters. 21(1)
The discovery of a novel series of 5-HT2C agonists based on a tricyclic pyrazolopyrimidine scaffold is described. Compounds with good levels of in vitro potency and moderate to good levels of selectivity with respect to the 5-HT2A and 5-HT2B receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fd92bc11aa8c6120cabf535e40752d2
https://pubmed.ncbi.nlm.nih.gov/21146986
https://pubmed.ncbi.nlm.nih.gov/21146986